Cingulate Inc.
Last updated September 27, 2026
Organization details
- Legal name
- Cingulate Inc.
- Ownership
- Public
- Status
- Active
- SIC code
- 2834 — Pharmaceutical Preparations
- Jurisdiction of incorporation
- Delaware
- Headquarters city
- Kansas City
- Headquarters state / province
- Kansas
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- CING
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001862150
- EIN
- 86-3825535
Board of directors
-
Bryan Jay Lawrence · DirectorSince 2024
-
Curtis Medeiros · DirectorSince 2023
-
Gregg Wm Givens · DirectorSince 2023
-
Jeffrey S. Ervin · DirectorSince 2024
-
John A. Roberts · DirectorSince 2024
-
Patrick Joseph Gallagher · DirectorSince 2023
-
Peter J. Werth · DirectorSince 2023
-
Scott Applebaum · DirectorSince 2023
-
Shane J. Schaffer · Director · Chief Executive OfficerSince 2023
-
Thomas Jeffrey Hargroves · DirectorSince 2026
Chief executives
Shane J. Schaffer
· Chief Executive Officer
Dates unknown
Director election results
Annual meeting of June 10, 2025. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
94.5%
Board connections
1 of this board's directors also sit on 1 other board.
- via Patrick Joseph Gallagher
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $656,964
- 5 purchases by 5 insiders
- Sold, last 12 months
- $0
- 0 sales by 0 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Mar 9, 2026 | Callahan Jennifer L. Officer (EVP and CFO) | Grant or award | +15,329 | — | — |
| Mar 9, 2026 | Shane J. Schaffer Director, Officer (Chief Executive Officer) | Grant or award | +6,862 | — | — |
| Mar 9, 2026 | Brams Matthew Officer (EVP and Chief Medical Officer) | Grant or award | +4,526 | — | — |
| Mar 9, 2026 | Patel Nilay Dahyabhai Officer (EVP, CLO and CCO) | Grant or award | +5,475 | — | — |
| Mar 9, 2026 | Silva Raul R. Officer (EVP and CSO) | Grant or award | +4,526 | — | — |
| Mar 9, 2026 | Callahan Jennifer L. Officer (EVP and CFO) | Shares withheld for tax | −6,427 | — | — |
| Mar 9, 2026 | Shane J. Schaffer Director, Officer (Chief Executive Officer) | Shares withheld for tax | −2,959 | — | — |
| Mar 9, 2026 | Brams Matthew Officer (EVP and Chief Medical Officer) | Shares withheld for tax | −1,025 | — | — |
| Mar 9, 2026 | Patel Nilay Dahyabhai Officer (EVP, CLO and CCO) | Shares withheld for tax | −2,086 | — | — |
| Mar 9, 2026 | Silva Raul R. Officer (EVP and CSO) | Shares withheld for tax | −1,828 | — | — |
| Feb 13, 2026 | Thomas Jeffrey Hargroves Director | Open-market purchase | +97,276 | $5.04 | $490,271 |
| Feb 6, 2026 | Peter J. Werth Director | Open-market purchase | +19,455 | $5.04 | $98,053 |
| Feb 6, 2026 | Callahan Jennifer L. Officer (SVP and CFO) | Open-market purchase | +4,864 | $5.04 | $24,515 |
| Feb 6, 2026 | Shane J. Schaffer Director, Officer (Chief Executive Officer) | Open-market purchase | +6,809 | $5.04 | $34,317 |
| Feb 6, 2026 | Brams Matthew Officer (EVP and Chief Medical Officer) | Open-market purchase | +1,946 | $5.04 | $9,808 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.